CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Files An 8-K Regulation FD DisclosureItem 7.01.Regulation FD Disclosure
On August1, 2017, CRISPR Therapeutics AG (the “Company”) announced the hiring and appointment of Tony W. Ho as the Executive Vice President, Head of Research and Development of the Company. A copy of the press release announcing Mr.Ho’s appointment is attached hereto as Exhibit 99.1.
The information in this Item 7.01 of Form 8-K, including the accompanying Exhibit 99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.
Item 7.01.Financial Statements and Exhibits.
(d)Exhibits:
The following exhibits shall be deemed to be furnished, and not filed:
|
ExhibitNo. |
Description |
| 99.1 | Press Release by CRISPR Therapeutics AG, dated August 1, 2017 |
CRISPR Therapeutics AG ExhibitEX-99.1 2 d435122dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 CRISPR Therapeutics Appoints Dr. Tony W. Ho to Head Research & Development ZUG,…To view the full exhibit click here
About CRISPR THERAPEUTICS AG (NASDAQ:CRSP)
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.
